FBLG - FibroBiologics, Inc. Common Stock

https://www.fibrobiologics.com

Recent News

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

GlobeNewswire • 3 days, 3 hours ago • score: 0.10

HOUSTON, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc. ( Nasdaq: FBLG ) ( "FibroBiologics" ) , a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and ...

Neutral

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

GlobeNewswire • 4 days, 3 hours ago • score: 0.07

Pilot studies underway to advance IND-enabling preclinical development Pilot studies underway to advance IND-enabling preclinical development ...

Bullish

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire • 1 month, 2 weeks ago • score: 0.16

HOUSTON, July 31, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc. ( Nasdaq: FBLG ) ( "FibroBiologics" ) , a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and ...

Neutral

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

GlobeNewswire • 1 month, 2 weeks ago • score: 0.10

HOUSTON, July 28, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc. ( Nasdaq: FBLG ) ( "FibroBiologics" ) , a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and ...

Neutral

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications - FibroBiologics ( NASDAQ:FBLG )

Benzinga • 1 month, 2 weeks ago • score: 0.08

HOUSTON, July 28, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc.

Neutral

FibroBiologics to Present at the Advanced Wound Care Summit USA

GlobeNewswire • 2 months ago • score: -0.01

HOUSTON, July 11, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc. ( Nasdaq: FBLG ) ( "FibroBiologics" ) , a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and ...

Neutral

FibroBiologics to Present at the Advanced Wound Care Summit USA - FibroBiologics ( NASDAQ:FBLG )

Benzinga • 2 months ago • score: -0.02

HOUSTON, July 11, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc.

Neutral

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank - FibroBiologics ( NASDAQ:FBLG )

Benzinga • 2 months ago • score: 0.11

HOUSTON, July 09, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc. FBLG ( "FibroBiologics" ) , a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and ...

Neutral

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

GlobeNewswire • 2 months, 1 week ago • score: 0.15

HOUSTON, July 07, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc. ( Nasdaq: FBLG ) ( "FibroBiologics" ) , a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and ...

Bullish

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

GlobeNewswire • 2 months, 4 weeks ago • score: 0.25

HOUSTON, June 16, 2025 ( GLOBE NEWSWIRE ) -- FibroBiologics, Inc. ( Nasdaq: FBLG ) ( "FibroBiologics" ) , a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$4.41

52W Low

$0.53

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

27.97

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

19.57%

Institutions (25–75% balanced)

12.26%

Shares Outstanding

41,889,100

Float

32,066,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-0.36

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-5.60%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—